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SUPPLEMENTARY NOTES
ABSTRACT
B7-H4 is a recently discovered B7-family molecule that has been shown to inhibit T cell proliferation and secretion of IL-2. Therefore, it has been classified as an immunosuppressive protein. Protein expression has been limited to subsets of activated T cells and is inducible in dendritic cells and macrophages. In contrast, protein expression is abundant on tissues from several malignancies, most notably breast adenocarcinoma. We proposed to generate antagonistic humanized anti-B7-H4 antibodies for the reversal of immune escape generated in breast cancer. Here we report the generation of 64 mouse monoclonal antibodies for the detection of B7-H4 by ELISA, and 25 for the detection of cell surface B7-H4 by flow cytometry. We are currently assessing the 25 antibodies suitable for flow cytometry for direct cytotoxic effect on human breast cancer cell lines as well as for antagonistic effects on B7-H4 function. Candidate antibodies will be subsequently humanized using genetic engineering techniques. Here, we also report several novel findings not yet reported in published literature and not anticipated in our grant proposal. 
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Introduction
In order for tumors to survive, the cancer must avoid elimination by the host's immune system either by avoiding detection or by inducing suppressive mechanisms.
Inhibition of the immune response in the tumor microenvironment can be accomplished by the secretion of immunosuppressive cytokines, like TGF-β, the recruitment of suppressor cells such as T regulatory cells and myeloid derived suppressor cells (MDSC), or the expression of immunomodulatory molecules at the cell surface like CTLA-4, PD-1, and B7-H4. B7-H4, the most recently discovered of the B7-like molecules, is not as well characterized as other cell surface suppressor molecules. Its mRNA expression is ubiquitous but its protein expression has been limited to subsets of activated T cells and antigen presenting cells [1] . Many human cancers also express B7-H4 such as renal cell carcinoma [2] , melanoma [3] , prostate cancer [4] , ovarian cancer [5] , and breast cancer [6, 7] . Recent characterization of the molecule has shown that B7-H4 can inhibit T cell proliferation and IL-2 secretion [8] , and thus, it has been hypothesized to protect tumor cells from T cell-mediated destruction. We proposed the development of a humanized antagonistic antibody to B7-H4 that could be used to treat B7-H4 expressing tumors such as breast cancer as a new immunotherapeutic approach for cancer patients.
Body
Specific Aim 1. Generation of an antagonistic humanized B7-H4 antibody.
Aside from characterization of B7-H4 expression in tumor tissues, almost all work with B7-H4 has been done in murine models. For the purpose of our studies with human tissues, we developed a human B7-H4-Fc fusion protein that consists of the extracellular domains of human B7-H4 fused to the Fc region of human IgG1 (Fig. 1) . In concurrence with published data in mice [8] , human B7-H4-Fc was able to bind to human T cells activated with anti-CD3/CD28 beads, as well as on some dendritic cells, macrophages, and B-cells (Fig. 2) , as detected by flow cytometry. Interestingly, in vitro activation of T cells, but not of the other cell populations, was required for expression of the B7-H4 receptor.
Using APC-labeled B7-H4-Fc, we have discovered B7-H4 receptors on several human lymphoma and leukemia cell lines. CEM, Karpas 299, and TLBR-1, cell lines derived from acute T-cell lymphoblastic leukemia, large cell anaplastic lymphoma, and breast implant-associated anaplastic large cell lymphoma, respectively, bound B7-H4-Fc, but Jurkat, an acute T-cell leukemia-derived cell line, did not bind B7-H4-Fc (Fig. 3 ).
This novel finding was unanticipated and exciting, as it open new doors to the study and treatment of hematopoietic malignancies. If engagement of the B7-H4 receptor with B7-H4 is able to inhibit lymphocytic proliferation, B7-H4-Fc may be able to be administered as treatment against malignant lymphocytes. Furthermore, B7-H4-Fc can also be used as a targeting molecule to deliver cytotoxic drugs to these malignant cells. This work on Tcell lymphomas was motivated by our need to find good B7-H4 receptor expressing cell lines that could be used in subsequent experiments.
In anticipation of developing antagonistic antibodies to B7-H4, we developed an assay to test the suppressive effects of B7-H4 on T cell proliferation isolated from peripheral blood of health donors. Surprisingly, however, our data could not reproduce the in vitro suppression achieved with murine B7-H4 on murine T cells [8] . Several possibilities may explain the discordance between our findings with human B7-H4 and published work using murine B7-H4. It may be that B7-H4 is an evolutionarily conserved molecule but whose function and signaling may be redundant or easily surmounted in humans versus mice. It may also be that B7-H4 may need to cluster, oligomerize, or be presented by viable cells in order to convey suppressive signaling. To elucidate the role of B7-H4 in the human immune system, we shifted our studies to the identification of the B7-H4 receptor on activated T cells. Identification of the receptor may provide important information about the function of B7-H4 in human tumors. It is also possible that antagonistic antibodies may bind either B7-H4 alone, its receptor, or the ligand/receptor complex so information about the molecular identity of the receptor is vital for these studies. We have already begun performing pull-down assays using B7-H4-Fc as bait. Initial studies performed by our laboratory have shown that the receptor is protease insensitive as suggested by digestion and flow cytometry experiments (Fig. 5) . Based upon these results, it is possible that the receptor is not a protein and other techniques need to be used to identify its molecular composition.
Even though in vitro studies with B7-H4-Fc did not suppress T cell proliferation, our goal has not changed to produce an antagonist human antibody. The abundance of B7-H4 on the surface of over 95% of breast cancer cases [6] , lack of protein expression in normal tissues, and its reverse correlation with prognosis [3,4,5] make B7-H4 an excellent target for antibody-mediated or directed therapy. In addition, intracellular B7-H4 has been shown to have anti-apoptotic effects in biliary epithelial cells from patients with primary biliary cirrhosis [9] . In biliary epithelial cells acquired from primary biliary cirrhosis, Chen et al. [9] showed that silencing of B7-H4 using RNA interference was able to induce apoptosis in those cells without the addition of other cells, like cytotoxic T lymphocytes, or cytotoxic molecules. It is conceivable that B7-H4 conveys protective effects in tumor cells apart from its immunomodulatory effects. An antagonist antibody can still be made to inhibit its other functions.
In preparation of producing a human or humanized antibody, studies were undertaken to produce murine hybridomas that may be used to define functional assays. Fig. 6) . By comparison, a commercial anti-B7-H4
antibody (H74, eBiosciences) was not able to bind SKBR-3, possibly due to its lower affinity or to the epitope that it binds.
Specific Aim 2. Evaluation of the clinical efficacy of B7-H4 antibodies in 4T1 murine
breast cancer model and in human breast tumor-bearing mice.
We have begun to screen for direct cytotoxic effects of the newly generated murine antibodies against B7-H4 positive (SKBR-3) and negative (JAR, HT29, and T47D) cell lines. We already have several promising antibodies yielding greater rates of apoptosis than HER-2 antibodies in SKBR3 (Fig. 7) . Humanization of these candidate antibodies will allow us to study these antibodies for antibody-dependent cell cytotoxicity and further study their therapeutic effects in SKBR-3 xenograft tumor models in mice.
We are currently assessing the immunosuppressive effects of human B7-H4-Fc on stimulated murine T cells in vitro. Because of the high homology between mouse and human B7-H4 (87%), there may be cross-species receptor binding. Furthermore, we will be screening the mouse monoclonal anti-human B7-H4 antibodies for reactivity to mouse B7-H4 by flow cytometry and for apoptotic activity. Those candidate antibodies will be used for studies in an in vivo 4T1 murine breast cancer model in BALB/c mice.  Tested direct cytotoxicity of candidate B7-H4 antibodies.
Reportable Outcomes
 Training grant application in review for the NIH Training Program at USC in Cellular, Biochemical, and Molecular Sciences.
Conclusion
We have generated a large selection of mouse anti-human B7-H4 monoclonal antibodies that we can now assess for antagonistic activity, antibody-dependent cellmediated cytotoxicity, complement-dependent cytotoxicity, and direct cytotoxicity.
Humanization of the antibodies with the highest activities will be performed in order to develop clinically applicable antibodies. More work still needs to be done characterizing the role of B7-H4 in the human setting. However, regardless of B7-H4's precise role in the immune response, the expression pattern of B7-H4 and its correlation with prognosis make B7-H4 an excellent target for antibody-mediated or directed therapy in breast cancer. After confirming some of our in vitro results, we will be ready for humanization of the antibodies and subsequent testing in vitro and in vivo. If the receptor for B7-H4 is identified, this would be a major milestone in the field since prior attempts by many groups have failed. It would also open the door to making a human antibody to the B7-H4 receptor which would represent another approach for inhibiting this ligand/receptor interaction on breast cancer cells.
We also report here novel findings not anticipated by our original grant proposal.
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